Sanctuary Advisors LLC Purchases Shares of 4,778 Glaukos Corporation $GKOS

Sanctuary Advisors LLC acquired a new position in shares of Glaukos Corporation (NYSE:GKOS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,778 shares of the medical instruments supplier’s stock, valued at approximately $668,000.

Other large investors have also recently made changes to their positions in the company. Allworth Financial LP bought a new stake in shares of Glaukos during the second quarter worth about $28,000. Los Angeles Capital Management LLC bought a new position in Glaukos in the 4th quarter valued at about $28,000. Larson Financial Group LLC lifted its position in Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares in the last quarter. Parallel Advisors LLC boosted its stake in Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in Glaukos by 111.4% during the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 215 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Gilbert H. Kliman sold 2,500 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the transaction, the director directly owned 37,406 shares of the company’s stock, valued at approximately $7,107,140. The trade was a 6.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Alex R. Thurman sold 20,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the completion of the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at $7,908,787.78. This trade represents a 31.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 113,025 shares of company stock worth $19,600,006 over the last 90 days. Company insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on GKOS. Wall Street Zen raised Glaukos from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Truist Financial upped their price target on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price target (up from $165.00) on shares of Glaukos in a research report on Thursday, July 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research report on Friday, July 17th. Finally, HC Wainwright raised their price objective on Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $178.08.

Glaukos Price Performance

Glaukos stock opened at $179.95 on Friday. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $191.62. The company’s 50 day moving average price is $162.64 and its two-hundred day moving average price is $133.95. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. The stock has a market cap of $10.61 billion, a P/E ratio of -55.37 and a beta of 0.78.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The firm had revenue of $185.61 million for the quarter, compared to the consensus estimate of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The company’s revenue was up 49.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.24) EPS. On average, equities analysts predict that Glaukos Corporation will post -0.32 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.